Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 05, 2026 | May 07, 2026 |
| BIOGEN INC.BIIB · Entity 1675 | EVP, Chief Financial Officer | February 10, 2025 | February 12, 2025 |
| Frontier Communications Parent, Inc.FTR · Entity 69025 | Director | April 01, 2019 | April 02, 2019 |
| IMS Health Holdings, Inc.Q · Entity 174539 | EVP and CFO | July 05, 2017 | July 07, 2017 |
| IQVIA HOLDINGS INC.IQV · Entity 3058 | EVP and CFO | July 05, 2020 | July 07, 2020 |
| MERIT MEDICAL SYSTEMS INCMMSI · Entity 3858 | Director | May 18, 2026 | May 19, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Director | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 14,647 |
Reported balance
After 2026-05-05 transaction · row 1
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 12,836 · Balance 14,647 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
BIOGEN INC.
Report date February 10, 2025 · Filed February 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,341 |
Ending reported balance
After 2025-02-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-10 · Exercise / conversion · Acquired 3,257 · Balance 25,712 Row 2 · 2025-02-10 · Tax withholding · Disposed 1,371 · Balance 24,341 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2025-02-10 | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-10 · Exercise / conversion · Disposed 3,257 · Balance 0 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.
Frontier Communications Parent, Inc.
Report date April 01, 2019 · Filed April 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 28,925.52 |
Reported balance
After 2019-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-01 · Grant · Acquired 14,018.69 · Balance 28,925.52 F1: Phantom stock units convert one-for-one into shares of common stock or cash equivalent, at the election of the Reporting Person, upon the Reporting Person's termination of service as a director of the Company. F2: Quarterly payment of portion of annual retainer paid in the form of phantom stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Phantom stock units convert one-for-one into shares of common stock or cash equivalent, at the election of the Reporting Person, upon the Reporting Person's termination of service as a director of the Company.
F2: Quarterly payment of portion of annual retainer paid in the form of phantom stock units.
IMS Health Holdings, Inc.
Report date July 05, 2017 · Filed July 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,517 |
Ending reported balance
After 2017-07-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-07-05 · Grant · Acquired 16,823 · Balance 56,590 F1: Represents a grant of restricted stock units that will vest in three annual installments beginning on July 5, 2018. Row 2 · 2017-07-05 · Tax withholding · Disposed 16,073 · Balance 40,517 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units that will vest in three annual installments beginning on July 5, 2018.
IQVIA HOLDINGS INC.
Report date July 05, 2020 · Filed July 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,966 |
Reported balance
After 2020-07-05 transaction · row 1
1 source rowRow 1 · 2020-07-05 · Tax withholding · Disposed 2,762 · Balance 18,966 |
MERIT MEDICAL SYSTEMS INC
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, No Par ValueSEC Table I · non-derivative | Direct | 9,852 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 3,457 · Balance 9,852 F1: The reported transaction involved the reporting person's receipt of a grant of 3,457 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. The RSUs granted to the reporting person will vest on May 3, 2027. Vesting of the RSUs is subject to continued service to the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction involved the reporting person's receipt of a grant of 3,457 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. The RSUs granted to the reporting person will vest on May 3, 2027. Vesting of the RSUs is subject to continued service to the issuer through the vesting date.
Moderna, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.80 · Expires 2036-07-08 | Direct | 7,415 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 7,415 · Balance 7,415 F1: This option will become fully vested and exercisable on July 8, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,618 |
Reported balance
After 2026-07-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-08 · Grant · Acquired 1,618 · Balance 1,618 F2: Restricted stock units convert into common stock on a one-for-one basis. F3: The shares subject to this restricted stock unit award will vest in full on July 8, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,733 |
Reported balance
After 2026-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-08 · Grant · Acquired 5,733 · Balance 5,733 F2: Restricted stock units convert into common stock on a one-for-one basis. F4: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will become fully vested and exercisable on July 8, 2027.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: The shares subject to this restricted stock unit award will vest in full on July 8, 2027.
F4: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 17:08 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 5,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000139 · form4.xml · derivative · entry 3 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,733 Underlying: Common Stock · 5,733 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 17:08 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 1,618 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000139 · form4.xml · derivative · entry 2 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,618 Underlying: Common Stock · 1,618 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on July 8, 2027. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on July 8, 2027. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 17:08 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 7,415 | $0.00 Strike: $73.80 | $0.00 |
DisclosureSEC source: 0001682852-26-000139 · form4.xml · derivative · entry 1 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,415 Underlying: Common Stock · 7,415 shares Expires 2036-07-08 F1 · derivative.exercise_date: This option will become fully vested and exercisable on July 8, 2027. Read SEC document |
| May 18, 2026 Filed May 19, 2026 22:02 UTC | MERIT MEDICAL SYSTEMS INC MMSI · Entity 3858 | GrantCommon Stock, No Par Value | 3,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001121897-26-000002 · form4-05192026_100552.xml · nonDerivative · entry 1 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,852 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 3,457 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. The RSUs granted to the reporting person will vest on May 3, 2027. Vesting of the RSUs is subject to continued service to the issuer through the vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032141 · wk-form4_1778184846.xml · nonDerivative · entry 1 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,647 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:06 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009023 · wk-form4_1771448783.xml · nonDerivative · entry 1 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,811 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 21:45 UTC | MERIT MEDICAL SYSTEMS INC MMSI · Entity 3858 | SaleCommon Stock, No Par Value | 1,750 | $94.51 | $165,392.50 |
DisclosureSEC source: 0001415889-25-015452 · form4-06032025_090648.xml · nonDerivative · entry 2 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,395 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:45 UTC | MERIT MEDICAL SYSTEMS INC MMSI · Entity 3858 | SaleCommon Stock, No Par Value | 1,750 | $94.30 | $165,025.00 |
DisclosureSEC source: 0001415889-25-015452 · form4-06032025_090648.xml · nonDerivative · entry 1 McDonnell Michael R. · CIK 0001121897 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,145 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:48 UTC | MERIT MEDICAL SYSTEMS INC MMSI · Entity 3858 | GrantCommon Stock, No Par Value | 2,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013718 · form4-05192025_100525.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,895 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,152 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 15, 2026. Vesting of the RSUs is subject to continued service to the issuer through the vesting date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 3,257 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004459 · form4.xml · derivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,257 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,371 | $142.54 | $195,422.34 |
DisclosureSEC source: 0001127602-25-004459 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,341 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004459 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003964 · form4.xml · derivative · entry 6 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,434 Underlying: Common Stock · 2,216 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,335 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003964 · form4.xml · derivative · entry 5 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,335 Underlying: Common Stock · 2,335 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 716 | $141.35 | $101,206.60 |
DisclosureSEC source: 0001127602-25-003964 · form4.xml · nonDerivative · entry 4 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,455 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003964 · form4.xml · nonDerivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 786 | $141.35 | $111,101.10 |
DisclosureSEC source: 0001127602-25-003964 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,955 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003964 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:53 UTC | MERIT MEDICAL SYSTEMS INC MMSI · Entity 3858 | GrantCommon Stock, No Par Value | 2,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013816 · form4-05202024_090554.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,743 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,431 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 16, 2025. Vesting of the RSUs is subject to continued service to the issuer through the vesting date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,684 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · derivative · entry 7 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,684 shares Expires 2024-02-18 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,152 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · derivative · entry 6 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,684 Underlying: Common Stock · 2,152 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionPerformance Stock Unit · Derivative | 4,568 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · derivative · entry 5 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,568 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,101 | $219.08 | $241,207.08 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 4 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,406 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,337 | $219.08 | $511,989.96 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,355 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 3,257 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004799 · form4.xml · derivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,257 Underlying: Common Stock · 3,257 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,431 | $240.98 | $344,842.38 |
DisclosureSEC source: 0001127602-24-004799 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,124 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004799 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,335 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004305 · form4.xml · derivative · entry 4 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,670 Underlying: Common Stock · 2,335 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 765 | $240.30 | $183,829.50 |
DisclosureSEC source: 0001127602-24-004305 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,298 Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004305 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:03 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004305 · form4.xml · derivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,650 Underlying: Common Stock · 6,650 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:34 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 4,568 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002810 · form4.xml · derivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,568 Underlying: Common Stock · 4,568 shares Expires 2024-02-18 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 18, 2021. The PSUs will vest on February 18, 2024. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,763 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · derivative · entry 7 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,763 shares Expires 2023-09-01 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]). Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,603 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · derivative · entry 6 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,763 Underlying: Common Stock · 2,603 shares Expires 2023-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]). Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · derivative · entry 5 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,682 shares Expires 2023-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vested in three (3) equal annual installments commencing one year after the grant date of 09/01/2020. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,332 | $267.17 | $355,870.44 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · nonDerivative · entry 4 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,728 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · nonDerivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,372 | $267.17 | $366,557.24 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,457 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023825 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed May 22, 2023 18:47 UTC | MERIT MEDICAL SYSTEMS INC MMSI · Entity 3858 | GrantCommon Stock, No Par Value | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008483 · form4-05222023_060528.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,312 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,262 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 18, 2024. Vesting of the RSUs is subject to continued service to the issuer through the vesting date. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,271 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006522 · form4.xml · derivative · entry 4 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,836 Underlying: Common Stock · 2,271 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,561 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006522 · form4.xml · derivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,107 Underlying: Common Stock · 2,561 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,310 | $278.38 | $364,677.80 |
DisclosureSEC source: 0001127602-23-006522 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,586 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006522 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 3,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005269 · form4.xml · derivative · entry 3 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,514 Underlying: Common Stock · 3,256 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,105 | $286.30 | $316,361.50 |
DisclosureSEC source: 0001127602-23-005269 · form4.xml · nonDerivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,896 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005269 · form4.xml · nonDerivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 7,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004579 · form4.xml · derivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005 Underlying: Common Stock · 7,005 shares Expires 2026-02-08 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.